BTAI earnings analysis
What we found in BTAI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioXcel reported approximately $0.2 million of second-quarter IGALMI® revenue, roughly flat with $0.206 million in the prior quarter but up from $0.12 million a year earlier; the filing does not provide current-quarter EPS, margin or cash-flow figures in the supplied text. The central investment issue is liquidity: the company had $13.8 million of cash, cash equivalents and restricted cash against $107.2 million of debt and acknowledged substantial doubt about its ability to continue as a going concern. The August 21, 2026 lender-acceptable transaction deadline, SEC investigation, TRANQUILITY data-quality concerns and pending regulatory and litigation matters materially outweigh the modest revenue improvement.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- IGALMI revenue grew year over year
- Three-month IGALMI® revenue was approximately $0.2 million, versus $0.206 million in 2026 Q1 and $0.12 million in 2025 Q2, implying roughly flat sequential performance and approximately 67% year-over-year growth based on the reported quarterly history.
- Commercial strategy remains focused
- Management reported $0.4 million of IGALMI® revenue for the six months ended June 30, 2026, while the company continues pursuing a lower-cost hospital/IDN contracting strategy and potential at-home label expansion.
- Near-term liquidity runway identified
- Management said cash, cash equivalents and restricted cash totaled $13.8 million at June 30, 2026 and were expected to fund operations and liquidity requirements through the end of August 2026.
- At-home sNDA remains under review
- The company submitted an IGALMI® supplemental NDA for at-home use on January 14, 2026. The FDA’s PDUFA target action date is November 14, 2026, subject to resolving the requested child-resistant package modification.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Critical financing and debt deadline
- The company reported aggregate principal indebtedness of $107.2 million at June 30, 2026 and stated that it did not have sufficient cash to fund operations and liquidity requirements through the end of August 2026. The Twelfth Amendment requires definitive lender-acceptable transaction agreements by August 21, 2026, creating an acute refinancing or strategic-transaction deadline.
- Going-concern uncertainty
- The filing states that substantial doubt exists regarding going-concern status because cash and liquidity were insufficient to support operations and service debt obligations for at least one year. Stockholders’ deficit was approximately $115.5 million at June 30, 2026, and six-month net loss was $27.4 million.
- SEC investigation and litigation exposure
- The SEC formal investigation, initiated in February 2024, concerns public disclosures about product sales, a Form 483 at a TRANQUILITY II clinical site and securities trading. The company cannot predict whether proceedings will be instituted or their impact on financing efforts.
- TRANQUILITY development may be delayed
- The FDA requested additional information regarding the reliability and consistency of PEC-score measurements in the TRANQUILITY program. FDA feedback indicated that the existing efficacy database included only 70 patients treated with the 60 mcg dose and would require additional efficacy and long-term safety data before an sNDA could be supported.
- Manufacturing and tariff cost pressure
- The company stated that a manufacturing facility of its sole active-pharmaceutical-ingredient supplier is subject to an FDA “official action indicated” status. Separately, a 100% tariff on certain imported patented pharmaceutical products and active ingredients becomes applicable to all other companies on September 29, 2026, potentially increasing manufacturing costs.
- Ongoing legal proceedings
- The preliminary approval of the securities-litigation settlement is not final; the hearing for final approval is scheduled for September 2, 2026. The filing also identifies additional derivative actions and continuing SEC-related proceedings that could create costs and divert management resources.
What they reported.
What the company itself reported, taken out of the document.
- Segment
- IGALMI® revenue: approximately $0.2 million for the three months ended June 30, 2026 and $0.4 million for the six months ended June 30, 2026; no reportable segment revenue breakdown was disclosed.
What they said about what is next.
No numeric operating guidance was provided. Management stated that cash, cash equivalents and restricted cash of $13.8 million as of June 30, 2026 was expected to fund operations and liquidity requirements through the end of August 2026, but there was no broader revenue or EPS outlook.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- BioXcel Therapeutics reported significant revenue growth and positive operational metrics in Q1 2026 compared to prior periods, although adjusted EPS showed wider losses than expected. Segment performance remains…
- 10-K · March 27, 2026
- The 2025 Form 10-K highlights positive clinical progress for BXCL501 (SERENITY at‑home Phase 3 met its primary objective on August 27, 2025) and an sNDA submitted January 14, 2026 seeking at‑home labeling for IGALMI®,…
- 10-Q · November 12, 2025
- BioXcel reported Q3 product revenue of $98 (in thousands) and GAAP diluted loss per share of $(2.18), missing consensus on both revenue and EPS. The company recorded a quarterly net loss of $30,911 (in thousands),…
- 10-Q · August 12, 2025
- BioXcel reported sharply lower product revenue of $120 thousand in Q2 2025 and a GAAP net loss of $19.187 million (EPS -$2.45). Gross margin collapsed to 10.8% in the quarter versus 94.4% in Q2 2024, while operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BTAI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever